MAM
Paytm Money appoints Varun Sridhar as CEO
NEW DELHI: India’s largest online investment & wealth management platform Paytm Money today announced the appointment of Varun Sridhar, as the new chief executive officer of Paytm Money. He will lead the launch & development of the equity brokerage other than growing the already successful mutual funds, NPS and Gold services. Under his leadership, the company will continue to simplify, innovate, and bring wealth management products to millions of Indians. He will be reporting to Amit Nayyar, president at Paytm.
Sridhar has led the digital transformation journey of some of the top retail banks in India and abroad. Most recently he served as CEO of FinShell India where he launched realme PaySa a fintech platform on mobile. Prior to this role, he was with BNP Paribas for close to eight years where amongst other assignments he supported the acquisition of Sharekhan. As a board member & member of the executive committee, he supported the scale-up of the digital equity brokerage & mutual fund business. He did his MBA from the prestigious SDA Bocconi School of Management, Milan Italy, and graduated from the University of Delhi.
Nayyar said, “Paytm Money is on a mission to empower millions of Indians with wealth management products. We are very excited to welcome Varun, whose experience in retail banking, broking, and wealth segment would help us accelerate our goals. I look forward to working closely with him to expand Paytm Money further."
Sridhar said, "I am thrilled to be part of the team that is responsible for introducing wealth management services to consumers in both India and Bharat and making meaningful financial inclusion simple & easy. At Paytm Money, I hope to build along with a fantastic team the most cost-effective & consumer-friendly products & experience for investors & traders. The wealth management and financial service solutions that Paytm is building are transforming the lives of millions of Indians and are relevant globally as well."
Paytm Money also announced that Amit Kapoor has joined as the new CFO & vice president for the company. Prior to this role, he was working with Aviva India as CFO of the life insurance company.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
